SCHEMBL4808358

SCHEMBL4808358

N#Cc1ccc(-c2n[nH]c3c2Cc2cc(C(=O)NCc4ccc(C(F)(F)F)nc4)ccc2-3)cn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 19/20 0.53
CHEK2 O96017 3/20 0.53
MARK2 Q7KZI7 2/20 0.53
SGK1 O00141 1/20 0.53
PRKCG P05129 1/20 0.53
AKT1 P31749 1/20 0.53
AKT2 P31751 1/20 0.53
AKT3 Q9Y243 1/20 0.53
AURKA O14965 2/20 0.46
CSF1R P07333 2/20 0.46
MARK3 P27448 2/20 0.46
FLT3 P36888 2/20 0.46
AURKB Q96GD4 2/20 0.46
LCK P06239 1/20 0.46
FGFR1 P11362 1/20 0.46
KDR P35968 1/20 0.46
ITK Q08881 1/20 0.46
JAK2 O60674 1/20 0.45
RPS6KB1 P23443 1/20 0.45
RPS6KA3 P51812 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6789724 0.87 CHEK1 (0.71) CHEK1CHEK2MARK2SGK1PRKCG
SCHEMBL4811632 0.82 CHEK1 (0.74) CHEK1CHEK2MARK2SGK1PRKCG
SCHEMBL4817862 0.76 CHEK1 (0.65) CHEK1CHEK2MARK2AKT1AKT2
SCHEMBL4814980 0.76 CHEK1 (0.79) CHEK1CHEK2MARK2SGK1AKT1
SCHEMBL4814976 0.76 CHEK1 (0.79) CHEK1CHEK2MARK2SGK1AKT1
SCHEMBL4810415 0.74 CHEK1 (0.64) CHEK1CHEK2MARK2AKT1AKT2
SCHEMBL4813399 0.72 CHEK1 (0.71) CHEK1
SCHEMBL4813383 0.72 CHEK1 (0.71) CHEK1
SCHEMBL4813279 0.71 CHEK1 (0.65) CHEK1CHEK2MARK2AKT1AKT2
SCHEMBL6787416 0.71 CHEK1 (0.81) CHEK1CHEK2MARK2SGK1PRKCG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7320986-B2 Fused tri and tetra-cyclic pyrazole kinase inhibitors ABBOTT LABORTORIES (US) 2008-01-22 US claimed
EP-1603885-A1 FUSED TRI AND TETRA-CYCLIC PYRAZOLE KINASE INHIBITORS Abbott Laboratories (US) 2005-12-14 EP claimed
US-20040259904-A1 Fused tri and tetra-cyclic pyrazole kinase inhibitors ABBVIE INC. 2004-12-23 US claimed
WO-2004080973-A1 FUSED TRI AND TETRA-CYCLIC PYRAZOLE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2004-09-23 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259904-A1 Fused tri and tetra-cyclic pyrazole kinase inhibitors TK1, MAP3K19, MAP3K20 CHEK1 73/4885CHEK2 36/4885MARK2 512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.